Square Pharmaceuticals (DHA:SQURPHARMA) Cyclically Adjusted Book per Share: BDT119.65 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:SQURPHARMA Square Pharmaceuticals PLC DHA:SQURPHARMA
94 GF Score
Price BDT214.70
GF Value BDT219.96
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Square Pharmaceuticals Cyclically Adjusted Book per Share?

Square Pharmaceuticals DHA:SQURPHARMA -0.42% 94 Cyclically Adjusted Book per Share is BDT119.65 as of Mar. 2026. GuruFocus rates DHA:SQURPHARMA with a GF Score™ of 94/100 and a GF Value™ of BDT219.96 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Square Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was BDT169.781. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is BDT119.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Square Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 12.90% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 15.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Square Pharmaceuticals was 20.20% per year. The lowest was 15.60% per year. And the median was 18.00% per year.

As of today (2026-09-10), Square Pharmaceuticals's current stock price is BDT214.70. Square Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was BDT119.65. Square Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.79.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Square Pharmaceuticals was 4.53. The lowest was 1.71. And the median was 2.54.


Square Pharmaceuticals  (DHA:SQURPHARMA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Square Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=214.70/119.65
=1.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Square Pharmaceuticals was 4.53. The lowest was 1.71. And the median was 2.54.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Square Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Square Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Square Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Square Pharmaceuticals Cyclically Adjusted Book per Share Chart

Square Pharmaceuticals Annual Data
Trend Mar16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.42 71.12 83.01 95.95 109.74

Square Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.99 109.74 113.56 116.13 119.65

DHA:SQURPHARMA vs ZTS, UTHR: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Square Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Square Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Square Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Square Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


DHA:SQURPHARMA
94GF Score
Square Pharmaceuticals PLC DHA:SQURPHARMA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Square Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Square Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=169.781/330.2130*330.2130
=169.781

Current CPI (Mar. 2026) = 330.2130.

Square Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 241.018 0.000
201609 48.659 241.428 66.553
201612 48.750 241.432 66.677
201703 52.237 243.801 70.752
201706 55.308 244.955 74.558
201709 58.980 246.819 78.908
201712 59.322 246.524 79.460
201803 62.179 249.554 82.276
201806 65.223 251.989 85.470
201809 68.892 252.439 90.117
201812 69.339 251.233 91.137
201903 72.942 254.202 94.753
201906 76.576 256.143 98.720
201909 80.109 256.759 103.027
201912 80.113 256.974 102.946
202003 83.989 258.115 107.449
202006 87.208 257.797 111.705
202009 92.505 260.280 117.360
202012 92.468 260.474 117.225
202103 96.427 264.877 120.212
202106 104.533 271.696 127.047
202109 108.706 274.310 130.860
202112 107.356 278.802 127.152
202203 112.394 287.504 129.090
202206 118.678 296.311 132.256
202209 122.838 296.808 136.663
202212 118.532 296.797 131.877
202303 123.333 301.836 134.928
202306 129.952 305.109 140.644
202309 136.790 307.789 146.756
202312 132.069 306.746 142.173
202403 137.387 312.332 145.252
202406 142.049 314.175 149.300
202409 149.763 315.301 156.846
202412 145.521 315.605 152.257
202503 151.938 319.799 156.886
202506 157.877 322.561 161.622
202509 167.497 324.800 170.288
202512 162.400 324.054 165.487
202603 169.781 330.213 169.781

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of BDT119.65 mean?
Square Pharmaceuticals (DHA:SQURPHARMA) has a Cyclically Adjusted Book per Share of BDT119.65 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Square Pharmaceuticals and its competitors.
Is Square Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Square Pharmaceuticals' current Cyclically Adjusted Book per Share is BDT119.65. Overall, Square Pharmaceuticals has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Square Pharmaceuticals' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Square Pharmaceuticals' Cyclically Adjusted Book per Share of BDT119.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Square Pharmaceuticals and its competitors. Square Pharmaceuticals's current Cyclically Adjusted Book per Share is BDT119.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Square Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Square Pharmaceuticals (DHA:SQURPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is BDT219.96, compared to a current price of BDT214.70 — trading 2.4% below its estimated fair value. The current Cyclically Adjusted Book per Share is BDT119.65. Square Pharmaceuticals' overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Square Pharmaceuticals (DHA:SQURPHARMA), the current Cyclically Adjusted Book per Share is BDT119.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Square Pharmaceuticals (DHA:SQURPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Square Pharmaceuticals stock appears to be undervalued. The current stock price of BDT214.70 is trading 2.4% below its estimated GF Value™ of BDT219.96. GuruFocus considers Square Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:SQURPHARMA:

  • Cyclically Adjusted Book per Share: BDT119.65
  • GF Value™: BDT219.96 vs. price of BDT214.70 (2.4% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the DHA:SQURPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Square Pharmaceuticals Business Description

Address Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212
Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceutical products, basic chemical products, animal health products, and crop care products, along with the manufacturing, marketing, and distribution of pharmaceutical products. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs for health care for all living species. It manufactures drugs such as paracetamol, clotrimazole, antiallergic, nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs, and also provides devices such as AnsuPen and AnsuPen Twist.
94GF Score

Get the complete analysis for DHA:SQURPHARMA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT214.70
Price
BDT219.96
GF Value